Mer­ck KGaA match­es lofty R&D goals with €250M in­vest­ment in­to a new clin­i­cal man­u­fac­tur­ing site in Switzer­land

As Mer­ck KGaA strives to prove it­self as a ca­pa­ble bio­phar­ma R&D play­er, it has be­gun con­struc­tion on a €250 mil­lion fa­cil­i­ty ded­i­cat­ed to de­vel­op­ing and man­u­fac­tur­ing drugs for use in clin­i­cal tri­als.

The Ger­man drug­mak­er chose a lo­ca­tion at Cor­si­er-sur-Vevey, Switzer­land, where it al­ready has a com­mer­cial man­u­fac­tur­ing site, in or­der to “bridge to­geth­er re­search and man­u­fac­tur­ing.”

“This in­vest­ment in the Mer­ck Biotech De­vel­op­ment Cen­ter re­flects our com­mit­ment to speed up the avail­abil­i­ty of new med­i­cines for pa­tients in need, and con­firms the im­por­tance of Switzer­land as our prime hub for the man­u­fac­tur­ing of biotech med­i­cines,” CEO Ste­fan Os­chmann said at the ground­break­ing cer­e­mo­ny, ac­cord­ing to a state­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER